Evidence map›Paper›PMID 39636884›Full record

ArticlePLOS global public health2024

Regional hotspots for chronic kidney disease: A multinational study from the ISN-GKHA.

Pablo Garcia, Anna K Strasma, Eranga Wijewickrama, Silvia Arruebo, Fergus J Caskey, Sandrine Damster, Jo-Ann Donner, Vivekanand Jha, Adeera Levin, Masaomi Nangaku and 7 more

Abstract read
In one paragraph

Article in PLOS global public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Pablo GarciaDivision of Nephrology, Department of Medicine, The University of New Mexico School of Medicine, Albuquerque, New Mexico, United States of America.
Anna K StrasmaDivision of Nephrology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, United States of America.ORCID https://orcid.org/0000-0001-5348-1707
Eranga WijewickramaDepartment of Clinical Medicine, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka.
Silvia ArrueboThe International Society of Nephrology, Brussels, Belgium.
Fergus J CaskeyPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.ORCID https://orcid.org/0000-0002-5199-3925
Sandrine DamsterThe International Society of Nephrology, Brussels, Belgium.
Jo-Ann DonnerThe International Society of Nephrology, Brussels, Belgium.ORCID https://orcid.org/0000-0002-5005-909X
Vivekanand JhaGeorge Institute for Global Health, University of New South Wales (UNSW), New Delhi, India.ORCID https://orcid.org/0000-0002-8015-9470
Adeera LevinDivision of Nephrology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.ORCID https://orcid.org/0000-0003-2438-8401
Masaomi NangakuDivision of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan.ORCID https://orcid.org/0000-0001-7401-2934
Syed SaadDivision of Nephrology and Immunology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.
Marcello TonelliDepartment of Medicine, University of Calgary, Calgary, Alberta, Canada.
Feng YeDivision of Nephrology and Immunology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.ORCID https://orcid.org/0000-0003-3601-8395
Ikechi G OkpechiDivision of Nephrology and Immunology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.ORCID https://orcid.org/0000-0002-6545-9715
Aminu K BelloDivision of Nephrology and Immunology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.ORCID https://orcid.org/0000-0002-6905-5937
David W JohnsonDepartment of Kidney and Transplant Services, Princess Alexandra Hospital, Brisbane, Queensland, Australia.ORCID https://orcid.org/0000-0001-5491-3460
Shuchi AnandDivision of Nephrology, Department of Medicine, Stanford University School of Medicine, Stanford, California, United States of America.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic kidney disease (CKD) disproportionately affects certain populations as demonstrated by well-established subnational geographic hotspots of CKD in Central America and South Asia. Using data from the third iteration of the International Society of Nephrology Global Kidney Health Atlas (ISN-GKHA), we aimed to systematically identify sub-national geographic or population clusters with high prevalence of CKD. The ISN-GKHA survey was conducted from July to September 2022, and included questions regarding whether a regional CKD hotspot existed in the respondents' country and possible contributors. A CKD hotspot was defined as a population cluster with a high risk of kidney failure requiring dialysis or transplant, or people dying from kidney failure. Overall, 46 out of 162 responding countries reported subnational hotspots for CKD within their country. Hotspots were reported across all regions, except for the Middle East. Latin America had the highest percentage (12 of 21, 57%) of countries reporting a regional CKD hotspot followed by the regions of North and East Asia, and Western Europe. Adults aged 18 to 44 years and rural populations were most commonly identified as the primary groups affected. Clinical factors were most commonly identified as contributors to CKD (hypertension in 74% and diabetes in 72%), followed by cultural (e.g., diet and herbal medications in 67%), and environmental (e.g., polluted water in 43%) factors. Latin American countries more commonly reported climate, cultural, and environmental factors as contributors compared to other regions. Across the world, there are a number of subnational regions where in-country experts identify a disproportionately higher burden of CKD, commonly occurring among younger age groups with clinical, cultural, and environmental contributors specific to these geographic regions. In-depth studies, starting with systematic epidemiology efforts, are needed to investigate the aetiopathogenesis of these CKD hotspots around the world so that tailored interventions can be offered.

Identifiers

PMID39636884
PMCPMC11620454

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.